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Abstract
Androgens drive the onset and progression of prostate cancer (PCa) by modulating androgen receptor (AR) transcriptional
activity. Although several microarray-based studies have identified androgen-regulated genes, here we identify in-parallel
global androgen-dependent changes in both gene and alternative mRNA isoform expression by exon-level analyses of the
LNCaP transcriptome. While genome-wide gene expression changes correlated well with previously-published studies, we
additionally uncovered a subset of 226 novel androgen-regulated genes. Gene expression pathway analysis of this subset
revealed gene clusters associated with, and including the tyrosine kinase LYN, as well as components of the mTOR
(mammalian target of rapamycin) pathway, which is commonly dysregulated in cancer. We also identified 1279 putative
androgen-regulated alternative events, of which 325 (,25%) mapped to known alternative splicing events or alternative
first/last exons. We selected 30 androgen-dependent alternative events for RT-PCR validation, including mRNAs derived
from genes encoding tumour suppressors and cell cycle regulators. Of seven positively-validating events (,23%), five
events involved transcripts derived from alternative promoters of known AR gene targets. In particular, we found a novel
androgen-dependent mRNA isoform derived from an alternative internal promoter within the TSC2 tumour suppressor
gene, which is predicted to encode a protein lacking an interaction domain required for mTOR inhibition. We confirmed
that expression of this alternative TSC2 mRNA isoform was directly regulated by androgens, and chromatin
immunoprecipitation indicated recruitment of AR to the alternative promoter region at early timepoints following
androgen stimulation, which correlated with expression of alternative transcripts. Together, our data suggest that
alternative mRNA isoform expression might mediate the cellular response to androgens, and may have roles in clinical PCa.
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Introduction
The growth, development and function of the prostate gland are
dependent on androgens, which affect gene expression via the
androgen receptor (AR), a steroid hormone receptor transcription
factor. AR transcriptional activity also drives the onset and
progression of prostate cancer (PCa) [1], the second leading cause
of male cancer-related deaths with ,899,000 men diagnosed
worldwide each year [2]. Cognate ligand-activated AR is thought
to exert its transcriptional effects via direct or indirect binding to
DNA sequences termed androgen response elements (AREs) [3,4].
Effective first and second line therapies for advanced PCa inhibit
endogenous androgen production and AR function [5], highlight-
ing the critical importance of AR signalling and downstream gene
targets in PCa biology.
Alternative mRNA isoforms with different exon contents can be
generated through variable alternative splicing patterns, and
selection of alternative transcriptional initiation and termination
sites. Using these mechanisms, mRNAs with different exon
combinations are transcribed from most (,70 to 90%) human
genes [6,7,8], and can encode proteins with different sub-cellular
localisations and functions. In addition to transcriptional effects,
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androgens and other steroid hormones are implicated in the post-
transcriptional regulation of gene expression [9,10,11,12,13]. AR
has also been shown to modulate expression of mRNA isoforms
regulated by alternative pre-mRNA splicing and promoter
selection [14,15]. In PCa, there is emerging evidence to suggest
that expression of specific splice isoforms derived from cancer-
relevant genes may underlie tumour biology and contribute to
clinical disease progression [15].
Several genome-wide studies have successfully identified
androgen-regulated transcriptional events using PCa models
[16,17,18,19,20,21,22], but have been unable to discern between
alternative mRNA species due microarray design or platform-
specific analysis issues. Newer splicing-specific microarrays and
high throughput sequencing (mRNA-Seq) approaches theoretical-
ly allow identification of all mRNA isoforms as well as
determination of gene expression in PCa [15]. An mRNA-Seq-
based analysis of the androgen-responsive LNCaP cell transcrip-
tome [22] was able to detect important differences in gene
expression, but did not achieve the required tag density to identify
quantitative changes in mRNA isoform abundance.
In this study, our objective was to identify androgen-regulated
alternative mRNA isoforms generated by alternative splicing and
from alternative transcriptional initiation sites due to promoter
selection. Screening for gene expression changes at exon-level
resolution also enabled us to identify novel AR-regulated genes
and associated pathways. In particular, we identified clusters of
novel androgen-regulated genes associated with, and including the
tyrosine kinase LYN, and a novel mRNA isoform derived from the
Tuberous Sclerosis Complex TSC2 tumour suppressor gene under
the control of an AR-dependent alternative internal promoter.
This novel TSC2 mRNA contains the reading frame for only the
carboxy (C)-terminal region of the tuberin protein, and was
predicted to lack an interaction domain required for heterodimer-
isation with hamartin to enable inhibition of the mammalian
target of rapamycin (mTOR) pathway, which is commonly
dysregulated in cancer.
Results
Exon-specific analyses of the androgen-responsive
LNCaP transcriptome identifies novel androgen-
regulated genes and mRNA isoforms
To monitor the global response of the LNCaP transcriptome to
androgen stimulation at single exon-level resolution, total RNA
was extracted from LNCaP cells grown in steroid-deplete medium
(n = 4) and following 24 hours of treatment (n = 4) with 10 nM
synthetic androgen analogue R1881. The 24 hour time point is
consistent with a recently published kinetic analysis of androgen-
regulated gene expression, which reported a robust genome-wide
transcriptional response to androgen stimulation after 24 hours
[17]. To confirm an AR-dependent transcriptional response, we
used qPCR to demonstrate up-regulation of KLK3 gene expression
in each of the treatment samples as compared with controls
(Figure S1). Using the Human Exon 1.0 ST Array, we profiled
expression of more than one million exons in a full genome-wide
screen to identify changes in the specific exon content of mRNA
transcripts as well as overall gene expression. We identified a total
of 287 genes that were up-regulated by at least 2-fold in response
to androgen treatment and 263 genes that were down-regulated by
at least 2-fold (Figure S1 and Table S1). GO analyses for the up-
regulated genes identified GO terms relating to sterol and lipid
metabolism, which were significantly enriched in the up-regulated
dataset (Figure S1). We were unable to identify any significantly
enriched terms in the down-regulated dataset. Compared with
previous analyses (for example, see reference [22]), the response to
androgens in this current study is thus typical of AR-regulated
gene expression (Figure S1).
Approximately half of the androgen–responsive genes identified
in our analysis have been previously found to be androgen-
regulated (Table S1) in at least one of seven previously published
datasets [16,17,18,19,20,21,22]. We did, however, additionally
identify a subset of 226 novel genes transcriptionally regulated in
response to androgens (Table S1) including LYN, which encodes a
tyrosine kinase implicated in PCa cell biology [23]. Western
analysis of lysates made from LNCaP cells grown in steroid-
deplete medium and following 24 hours androgen treatment
confirmed that the fall in LYN mRNA expression equated to a fall
in LYN protein expression (Figure 1A). We next used the IPA
‘‘Core Analysis’’ function to identify clusters of novel androgen-
regulated genes associated with, and including the tyrosine kinase
LYN (Figure 1B). Using RT-PCR, we confirmed statistically-
significant up-/down-regulation of LYN and eleven LYN-associated
genes relative to GAPDH expression in each of the treatment
samples as compared with controls (p,0.05) exactly as predicted
by our microarray analysis (Figure 1B). The validation rate (100%)
suggests that our microarray analysis is a robust description of
androgen-dependent transcriptional changes in PCa cells.
To detect changes in mRNA isoform ratios in response to
androgen stimulation we applied PLIER/Iter-PLIER statistical
analysis to exon level data along with several filtering criteria (see
Materials and Methods). We identified a total of 1279 differentially
expressed probesets (p,0.001), of which 325 (,25%) mapped to
well known alternative splicing events (n = 108; 8.4%), alternative
first exons/59 ends (n = 144; 11.3%) and alternative last exons/39
ends (n = 73; 5.7%). The remaining probesets did not have obvious
annotations. In view of previously-published data [14,15], we
focussed solely on cassette exons and changes in extreme 59-ends
of transcripts (alternative transcriptional initiation sites due to
alternative promoter selection) for which there were full length
annotated UCSC (University of California, Santa Cruz) gene
sequences [24] available based on RefSeq or GenBank entries with
known exon connectivity. Probe intensities of candidate transcripts
were visualised at single exon level using EASANA to select
candidates that might encode potentially androgen-regulated
alternative mRNA isoforms for experimental verification. We
identified a total of 30 candidate mRNA isoforms, of which 7 were
positively validated in the array sample set as well as an
independent dataset (Figures 2 and 3, and fully described below).
In each validated case we found statistically significant differences
(p,0.05) in actual biological ratios of constitutive and alternative
(androgen-regulated) mRNA isoforms as monitored by multiplex
RT-PCR and fluorescent quantification after capillary agarose gel
electrophoresis (Figure 3). In each case, RT-PCR products were
sequenced to verify the content of individual mRNA species.
Identification of mRNAs containing androgen-regulated
cassette exons
There are two fully annotated mRNA isoforms from the
NDUFV3 gene (RefSeq accession numbers NM_021075 and
NM_001001503), which encodes a subunit of the NADH-
ubiquinone oxidoreductase complex. Our analysis suggested
differential androgen-regulated production of these two isoforms,
with androgen-dependent skipping of a cassette exon (exon 3)
within the mRNA transcript. Although no direct function for this
gene product has been described in PCa, mitochondrial complex I,
of which the NDUFV3 protein is a component, plays an important
role in interferon-beta and retinoic acid-induced cancer cell death.
The long (1095 nt; nucleotide) cassette exon within the NDUFV3
Androgen-Dependent Exons
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transcript inserts coding information for a 365 amino acid (aa)
peptide into the NDUFV3 protein sequence compared with the
shorter mRNA isoform (Figure 2, NCBI NP_066553 and
NP_001001503.1 respectively). Multiplex RT-PCR demonstrated
expression of exon 3-included and exon 3-skipped transcripts in
steroid-deplete conditions, and confirmed an androgen-dependent
switch in exon 3 inclusion (Figure 3A, compare lanes 1–4 with 5–
8). Following androgen treatment there was a ,2 fold increase in
the exon-skipped product relative to the exon-included product
(Figure 3B).
Androgen-regulated inclusion of a cassette exon was also
identified in the transcript derived from the gene encoding the
putative transcription factor ZNF121. ZNF121 encodes a 390
amino acid protein with 9 C2H2-type zinc finger motifs
(Figure 2C), and is expressed as three alternative mRNA isoforms
(UCSC mRNA isoforms uc010xkp.1, uc010dwt.2 and
uc010xkq.1, respectively). Exon 2 is alternatively-spliced within
the 59 untranslated region (UTR), while inclusion of exon 5
interrupts the reading frame initiated in exon 4, and results in a
frameshifted mRNA (Figure 2A and 3B). Using multiplex RT-
PCR, exon 2 was found to be constitutively skipped in LNCaP
cells (data not shown), but inclusion of the 58 nt exon 5 was
significantly up-regulated in response to androgen treatment
(Figure 3A, compare lanes 1–4 with lanes 5–8). In terms of
functional outputs, cassette exon 5 introduces a frameshift to the
ZNF121 protein sequence very close to the amine (N)-terminus of
Figure 2. Overview of identified androgen-regulated mRNA isoforms. (A) Cartoon of intron/exon structure of gene, showing the splicing
pattern and the positions of the primers (shown as arrows) used for RT-PCR. Genes are annotated with the androgen responsive splicing/promoter
selection event above the gene (exons joined by broken lines in black), and constitutive event below the gene (exons joined by broken lines in grey).
The androgen-regulated exons are shown in black, and weakly androgen-dependent exons indicated in grey. Constitutive exons are indicated in
white. The positions of the primers used for RT-PCR validation are shown below exons as arrows, and predicted position of alternative promoters are
shown as angled arrow. (B) For each gene a pair of alternative mRNA transcript isoforms is shown. (C) The predicted full-length proteins made from
each of the genes are indicated, along with the position of conserved domains. These are abbreviated: ZF = zinc finger motif; HDc =metal dependent
phosphohydroxylate with conserved HD motif; PolIII = DNA polymerase subunits gamma and tau; CC= coiled coil domain; Tub= tuberin superfamily;
Rap/GAP= RAP/GTPase Activating Protein superfamily; PDZ=protein interaction and binding domain; C2 =protein kinase C conserved domain 2 Ca2+
binding motif; STYKc = STYK protein kinase domain.
doi:10.1371/journal.pone.0029088.g002
Figure 1. Expression of LYN and -associated genes are androgen-regulated in LNCaP cells. (A) Western analysis of LYN and actin (loading
control) protein expression in cells grown in full medium, steroid-deplete medium, and following 24 hours of treatment with 10 nM R1881. (B)
Ingenuity Pathway Analysis (IPA) of LYN-associated genes. Novel androgen-regulated genes identified in the present study are labelled in shades of
red (up-regulated genes) or shades of green (down-regulated genes). (C) Expression of 12 novel androgen-regulated genes associated with LYN in
steroid-deplete conditions (2, lanes 1–4) and after 24 hours of treatment with 10 nM R1881 (+, lanes 5–8) measured by multiplex RT-PCR. Levels of
transcript expression were normalised to GAPDH levels, and data from experimental quadruplicates were used to obtain the mean 6 SE for each
transcript. A particularly high level of androgen-mediated gene activation was seen for the FZD5 gene, which encodes a transmembrane Wnt5a
receptor. Other confirmed up-regulated genes included KITLG, which encodes the Kit ligand upstream of LYN in the pathway, and MTOR, which
encodes a key regulator of cell growth. Similarly, we confirmed down-regulation of the novel androgen-regulated genes REDD1 (also known as
DDIT4), which negatively regulates mTOR, and DEPDC6 which encodes an mTOR interacting protein.
doi:10.1371/journal.pone.0029088.g001
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Figure 3. Androgens regulate expression of a number of alternative mRNA isoforms in LNCaP cells. (A) Capillary agarose gel
electrophoretic analysis of RT-PCR products amplified from mRNA from cells grown either in steroid-deplete medium (lanes 1–4) or after 24 hours of
treatment with 10 nM R1881 (lanes 5–8). The predicted mRNA isoforms detected are shown to the right of each gel exactly as summarised in
Figure 2B. (B) Fluorescent quantification was performed to obtain the relative normalised expression ratio, which is the contribution of the PCR
product representing the alternative (androgen-regulated) transcript/constitutive transcript or 39 transcript end/59 transcript end. Data from the
experimental quadruplicates (gel image) were used to obtain the mean 6 SE.
doi:10.1371/journal.pone.0029088.g003
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the encoded protein, and so may either destabilise the mRNA
through the NMD pathway [25] or lead to production of a protein
lacking zinc finger motifs (Figure 2C).
Identification of mRNAs with distinct androgen-regulated
59 ends
We also identified variant mRNA isoforms with alternative 59
exons generated in response to androgen treatment from
alternative transcriptional initiation sites due to alternative
promoter selection. These included mRNA isoforms from the
PDE4D gene, which encodes a cAMP-specific phosphodiesterase
involved in signalling pathways, and has been recently identified as
a proliferation-promoting factor up-regulated in clinical PCa [26].
The PDE4D gene is transcribed using an array of five alternative
transcriptional initiation sites, including distinct promoter elements
upstream of exon 1 (which is spliced onto exon 2 and then 7
(RefSeq NM_001165899) and upstream of exon 3 which is also
directly spliced onto exon 7 (RefSeq NM_006203)) (Figure 3A)
[26]. Using multiplex RT-PCR, LNCaP cells were found to
initiate PDE4D transcription upstream of exon 3 in steroid-deplete
conditions, and following androgen treatment a dramatic switch in
transcriptional initiation was made to the promoter upstream of
exon 1 (Figures 2 and 3). Both these PDE4D mRNA isoforms
contain predicted ORFs for the conserved HDc motif of metal
dependent phosphohydrolases (Figure 2C), but have different N-
terminal sequences (NCBI NP_001159371.1 and NP_006194.2).
A switch between androgen-regulated mRNA isoforms with
distinct 59 ends was also identified for the TACC2 gene, which
encodes a centrosomal protein. Multiple different TACC2 mRNA
isoforms are transcribed from the TACC2 gene, under the control
of alternative internal promoters upstream of exons 14, 15, and 18
(Figure 2A) to give different mRNA isoforms with alternative exon
contents [27]. Using multiplex RT-PCR using primers comple-
mentary to exons 12 (59 end of the gene) and 21 (39 end of the
gene), we confirmed significantly increased levels of 39 end of the
TACC2 gene as compared with the 59 end following androgen
treatment, suggesting androgen-regulated mRNA isoform produc-
tion through an alternative internal AR-activated promoter
(Figure 3). The use of a promoter upstream of exon 15 produces
a variant mRNA isoform called AZU-1, in which the coding
information for the coiled-coil domain is preserved (GenBank ID:
AF176646.1). Although TACC2 is a non-essential gene and its
deletion does not cause cancer in mice, [28,29], up-regulation of
AZU-1 has been implicated in advanced breast cancer [28]. We
analysed expression of mRNA isoforms containing TACC2 exons
14, 15 and 18 which are the first exons of each of these annotated
transcription units, and found that the promoter upstream of exon
15 is androgen-responsive, indicating AZU-1 is an androgen-
regulated transcription unit (data not shown).
Androgen-regulated selection of alternative 59 ends were also
detected in transcripts derived from the TSC2, RIMS1 (regulating
synaptic membrane endocytosis 1) and WEE1 genes. TSC2 encodes an
important tumour suppressor protein tuberin, which regulates cell
growth [30,31]. The TSC2 gene is complex and encodes a number
of different mRNA isoforms with alternative exons, and our
analysis predicted increased levels of transcription of the
downstream region of the gene. Confirming this by multiplex
RT-PCR using primers within exons 8 and 10 (59 end) and 41 and
42 (39 end), we observed an ,2 fold increase in expression of 39
end of the TSC2 gene as compared with the 59 end following
androgen treatment (Figure 3A, compare lanes 1–4 with lanes 5–
8). Known annotated mRNA isoforms on UCSC [24,32] indicated
two known alternative internal promoters upstream of TSC2 exon
33 (Figure 2A), which might to respond to androgen stimulation
(DP1 and DP2). The alternative TSC2 transcript produced in
response to androgen treatment contains coding information for
the Rap/GAP domain of the full-length protein, but is missing the
tuberin family domain (Figure 2C) (GenBank BAG52831.1).
Androgen-regulated mRNA isoforms were also predicted within
the RIMS1 gene, which is a member of the RAS gene superfamily,
and encodes a protein that acts as a scaffold to regulate vesicle
exocytosis. UCSC gene annotations [24,32] indicate that RIMS1
encodes a family of 11 different mRNA isoforms, transcribed
downstream of 5 promoters. By multiplex RT-PCR using primers
within exons 8 and 9 (59 end) and exon 34 and 35 (39 end), we
observed an ,3 fold increase in expression of 39 end of the RIMS1
gene as compared with the 59 end following androgen treatment
(Figure 3A compare lanes 1–4 with 5–8, and Figure 3B), most
likely generated from transcriptional initiation from the UCSC
annotated promoters upstream of exon 13 (Figure 2A) [24,32].
The alternative transcripts produced in response to androgen
treatment contain a predicted ORF, which excludes a PDZ
domain involved in protein interactions and binding, and one
calcium-binding (C2, protein kinase C conserved domain 2)
domain (Figure 2C) compared with the full length protein.
In the above examples, androgen treatment led to alternative
promoter selection and an increase in expression of an alternative
mRNAs from a particular transcription start site. In contrast, we
observed more subtle selective androgen-dependent alternative
promoter usage within the androgen down-regulated WEE1 gene.
WEE1 encodes an important nuclear tyrosine kinase, which
functions as a negative regulator of cell cycle progression and
inhibits Cdc2-Cyclin B activity and entry into mitosis. UCSC
annotations and published analyses of mRNA isoforms [24,32,33]
indicate that WEE1 encodes two alternative mRNAs initiating
upstream of exon 1 (isoform 1 encoding full length Wee1 protein)
or exon 2 (isoform 2 encoding a shorter protein Wee1i with an
alternative N-terminus) (Figure 2). Both the long and the shorter
forms of WEE1 protein contain the STY protein kinase domain
(STYKc), but the shorter WEE1i does not contain the 214 aa N-
terminus domain which mediates ubiquitin-dependent degrada-
tion of WEE1 protein to trigger mitotic entry [33]. Multiplex RT-
PCR indicated that both WEE1-derived transcripts were down-
regulated following androgen treatment, however the longer
mRNA isoform (RefSeq NM_003390) was down-regulated to a
greater extent as compared with the shorter mRNA isoform
(RefSeq NM_001143976) (Figure 3A, compare lanes 1–4 with 5–
8). The relative (,3 fold) increase in abundance of the shorter
mRNA isoform (and possibly Wee1i protein) following androgen
treatment may provide the cell with constitutive WEE1-like kinase
activity (protein NCBI NP_001137448.1) to regulate androgen-
induced cell cycle progression (Figure 3B).
Novel mRNA isoforms are regulated by endogenous
androgens and expressed in benign prostate epithelial
cells as well as clinical PCa
We validated the above findings using a natural androgen
(dihydrotestosterone; DHT) at physiological concentrations (1 nM
and 10 nM), as well R1881 at 1 nM concentration, which is thought
to positively affect cell proliferation [21] (Figure S2). RT-PCR was
performed using total RNA extracted from LNCaP cells grown in
steroid-deplete medium and following 24 hours of treatment with
different concentrations of R1881 or DHT. The absolute
magnitude of the actual biological ratios of constitutive and
alternative (androgen-regulated) mRNA isoforms varied for each
transcript depending on the dose of R1881 and DHT. Although
expression of the alternative mRNA isoform encoded by WEE1 was
not affected by 1 nM R1881, differential expression was observed
Androgen-Dependent Exons
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following treatment with 1 nM and 10 nM DHT. DHT (at both
1 nM and 10 nM concentrations) did not have an effect on
expression of the alternative mRNA isoform derived from RIMS1,
however expression changes were seen with 1 nM R1881. For other
transcripts, an overall trend was observed towards relative increased
expression of androgen-regulated mRNA isoforms in keeping with
the data with 10 nM R1881. These findings suggest that the
functional cellular response to androgens mediated by alternative
mRNA isoform expression may be dependent on the local
(physiological) concentration of endogenous ligand.
To determine whether the identified androgen-dependent
mRNA isoforms are cancer-specific and cell line-specific, we
examined the expression of alternative mRNAs in other
tumourigenic androgen-dependent (CWR22Rv1) and androgen-
independent (LNCaP-AI, LNCaP-cdxR) PCa cell lines, as well as a
non-tumourigenic androgen-independent prostate epithelial cell
line (BPH-1) (Figure S3). Since we were examining the steady-state
levels of mRNA expression (rather than dynamic changes in
response to androgens), we focussed on the alternative mRNAs
(derived from NDUFV3, ZNF121, PDE4D, and WEE1) that could
be specifically detected with our RT-PCR assays in steady-state
conditions (culture medium containing androgens). Androgen-
responsive exons were not exclusive to cancer cells (expressed in
BPH-1 cells), nor to PCa cell lines that exhibit an androgenic
growth response (LNCaP, and CWR22Rv1). In addition,
alternative mRNA isoforms were present in LNCaP cells cultured
in medium devoid of steroids (LNCaP-AI) and with anti-
androgens (LNCaP-cdxR) (Figure S3A). To demonstrate that
AR is required to mediate androgen-regulated expression of
alternative mRNAs, we examined expression of alternative exons
in PCa cell lines that do not exhibit an androgenic growth
response (DU145, PC-3, PC-3M) (Figure S3B). Although alterna-
tive exons were expressed in these cell lines, treatment with
androgens did not alter their expression levels.
Finally, we studied expression of alternative mRNA isoforms
(derived from NDUFV3, ZNF121, PDE4D, and WEE1) in prostate
biopsies from patients with PCa (Figure S3C), and found that
although alternative exons were expressed in clinical PCa, there
was no association with disease progression (p.0.05). Taken
together, the above data suggest that in addition to androgens,
expression of alternative mRNAs may be regulated by other trans-
acting factors as well as cis-regulatory elements in a cell type- and
tissue-specific manner.
Expression of novel mRNA isoforms is both directly and
indirectly regulated by androgens
Recent studies have used chromatin immunoprecipitation
(ChIP) and direct next generation sequencing (ChIP-Seq) for
unbiased mapping of AR genomic binding sites in LNCaP cells in
response to androgens [3,34]. To determine whether the
association of AR within candidate genes identified in our study
may drive the expression of alternative mRNA isoforms, we
compared the previously published AR binding profiles [3,34] to
the predicted locations of alternative events (Figures 4A and S4).
The genomic loci of AR binding sites were uploaded to UCSC
genome browser [24], and interrogated for positively-validating
genes of interest from our present study (Figure 2). In keeping with
our hypothesis, AR binding (Figure 4A, LNCaP AR ChIP-seq
peaks, and Figure S4) was observed close to alternative promoters
predicted to yield variant androgen-regulated mRNA isoforms
with alternative 59 exons generated from alternative transcription-
al initiation sites (PDE4D, TACC2, TSC2, RIMS1, and WEE1).
However, we did not observe AR binding within genes encoding
transcripts identified to possess androgen-regulated cassette exons
(NDUFV3 and ZNF121) suggesting that these splicing events may
be due to the indirect effect of androgens.
To test this hypothesis, we co-treated LNCaP cells with or
without 10 nM R1881 (as above) in conjunction with the
translational inhibitor cycloheximide or vehicle (dimethylsulfoxide;
DMSO) (Figure 4B). Using multiplex RT-PCR, we monitored
exon skipping and exon inclusion within transcripts derived from
NDUFV3 and ZNF121, respectively. Cycloheximide completely
inhibited androgen-dependent NDUFV3 exon 3 skipping and
ZNF121 exon 5 inclusion. These data indicate that the effect of
androgens on NDUFV3 and ZNF121 splicing is indirect and
requires intermediate protein synthesis.
Ligand-activated AR is rapidly recruited to an alternative
internal promoter within the TSC2 gene
To determine whether AR can directly regulate alternative
mRNA expression from alternative transcription start sites, we
explored the association of AR with the TSC2 gene. To test our
hypothesis that the alternative TSC2 mRNA isoform is directly
androgen-regulated, we firstly examined expression of TSC2
mRNAs from LNCaP cells co-treated with or without 10 nM
R1881 (as described above) in conjuction with cycloheximide or
vehicle (DMSO) (Figure 5A). Cycloheximide did not have any
significant effect (P.0.05) on expression of androgen-induced
mRNA isoform expression indicating that the ligand-dependent
effect of AR on the TSC2 gene is direct and does not require
intermediate protein synthesis.
To confirm this hypothesis, we examined the dynamic
recruitment of ligand-activated AR to alternative internal
promoters (Figure 4A) of TSC2 by ChIP at early timepoints
following androgen stimulation. LNCaP cells were cultured in
steroid-deplete medium to quiesce AR activity, and subsequently
treated with 10 nM R1881 as the only available steroid and AR
ligand. Chromatin was harvested at 60-minute intervals following
androgen treatment, and subjected to immunoprecipitation using
anti-AR antisera. Recovered genomic DNA was analysed by
qPCR to examine recruitment of AR protein to the DP1 and 2
(Figure 4B, left and right panels, respectively) as well as a region of
the TSC2 gene that was not predicted to bind AR. Maximal
recruitment of AR to both DP1 and 2 was observed after
120 minutes following androgen stimulation, but not to the non-
AR-binding region within GREB1. Overall these data show that
AR is dynamically recruited to DP1 and 2 within TSC2, in
response to ligand activation. Due to close proximity of the
promoters (separated by 524 nucleotides), it was difficult to cleanly
resolve the association of AR-promoter association.
Since AR-dependent gene expression is a dynamic process [17], we
measured the expression of the shorter AR-regulated TSC2 isoform
by RT-PCR at timepoints up to 24 hours following androgen
stimulation (Figure 4C). We observed an increasing temporal trend in
expression of the alternative TSC2 isoform, which reached statistical
significance at 16 hours following androgen stimulation (p,0.05).
Taken together, these data suggest that recruitment of ligand-
activated AR to internal androgen-regulated promoters controls
expression of an alternative TSC2 mRNA isoform. Although we
observed a lag in alternative isoform expression ratios following AR
recruitment to the DP1 and 2 promoters, this is likely explained by
the stability of the constitutive mRNA isoform and the time taken to
establishment of steady-state levels.
Discussion
In the present study, we have undertaken gene expression
analysis at exon level resolution to identify androgen-regulated
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production of both novel genes and endogenous variant mRNA
isoforms. Gene expression pathway analysis revealed clusters of
novel androgen-regulated genes associated with, and including the
tyrosine kinase LYN, which is required for PCa cell proliferation
[23]. Our experimental data indicates that LYN expression is
normally repressed by androgens both at the mRNA and the
protein level. We also identified androgen-dependent up-regula-
tion of the LYN-associated kinase mTOR. mTOR kinase activity
has been previously found to be up-regulated in PCa cells in
response to androgens [35], and the mTOR pathway is important
in clinical PCa, particularly in tumours lacking expression of
PTEN (phosphatase and tensin homolog). Since AR gene targets
can remain active in CRPCa, the mTOR complex may be a
possible therapeutic target for CRPCa [35,36].
Exon resolution analyses further identified a number of mRNA
isoform switches that occur in response to androgen treatment,
including selection of alternative 59 exons and inclusion of cassette
exons. The oestrogen receptor (ER) has been recently shown to
regulate expression of many mRNA isoforms from alternative
transcriptional initiation sites as are result of alternative promoter
selection [13]. ER was found to associate with alternative
promoters regions, and ER-regulated alternative mRNA isoforms
influenced breast cancer cell behaviour. Similarly, based upon
published data [3], we predicted the association of AR to
alternative promoter regions within candidate genes, and con-
firmed AR binding to an alternative promoter region (comprising
DP1 and 2) within the TSC2 gene. This association directly
regulated the dynamic accumulation of a shorter TSC2 mRNA
predicted to encode a 508 aa C-terminus peptide up to 24 hours
after androgen addition (GenBank protein accession:
BAG52831.1). This peptide lacks an interaction domain needed
to form a heterodimer with TSC1 (hamartin), which is required to
regulate mTOR kinase function. Although primarily characterised
as an upstream regulator of mTOR, TSC2 also has been
associated with mitotic structures and cell cycle control, and in
particular the C-terminus of the full-length protein has been
localised to the nucleus and associated with the transcriptional
activity of FOXO transcription factors [37]. We are currently
exploring our hypothesis that this novel AR-regulated TSC2
mRNA isoform might play an important role in mTOR regulation
in PCa cells.
In principle, ExonArrays should provide an extremely accurate
measure of gene expression [38] since data are gathered along the
full length of the transcript. Compared with other published
datasets on androgen-regulated gene expression [16,17,18,19,
20,21,22], the results of our analysis have the most extensive
overlap with other microarray analyses. Although ,50% of gene
expression changes in our dataset were novel, these findings may
be in part due to experimental differences between previously
published studies rather than platform-specific differences (Table
S2). Indeed, a more detailed analysis suggested that many of the
novel hits are in fact functionally related to known androgen-
regulated genes (see Table S2, column 5). Of the 1279 putative
androgen-regulated alternative events identified, only ,25%
mapped to known alternative splicing events or alternative first/
last exons. Furthermore, the low positive validation rate (,23%)
highlights the technical challenges of using ExonArrays to identify
alterations in alternative mRNA isoform expression on a
background of large changes in gene expression [15]. Taken
together, our analyses suggest that the bulk of androgen-regulated
effects on the transcriptome are at the level of overall gene
expression rather than alterations in the expression of variant
mRNAs.
In summary, we have found that androgens not only have
quantitative effects on gene expression but also have some
qualitative effects on transcript composition. While different
molecular mechanisms may underlie androgen-regulated expres-
sion of alternative mRNAs (including alternative splicing,
transcriptional initiation or RNA stability) in a cell line- and
tissue-specific manner, our data suggest that androgens directly
regulate expression of alternative 59 exons (as a result of promoter
selection), and indirectly regulate alternative splicing. The
androgen-dependent variant transcripts identified in this study
are predicted to yield protein isoforms that may mediate the
cellular response to androgens, although the functional roles of
these mRNA isoforms in clinical PCa is as yet unknown, and
warrants further investigation.
Materials and Methods
Antibodies
The following antibodies were used: anti-LYN mouse mono-
clonal antibody (65038-1-1 g, Proteintech), anti-AR rabbit anti-
sera (C19, Santa Cruz Biotechnology), anti-actin rabbit antisera
(A-2066, Sigma), and normal rabbit IgG (sc-2027, Santa Cruz
Biotechnology).
Cell line samples for array analysis and RT-PCR validation
All cells were grown at 37uC in 5% CO2. LNCaP cells (CRL-
1740, ATCC) were maintained in RPMI-1640 with L-Glutamine
(PAA Laboratories, R15-802) supplemented with 10% Fetal
Bovine Serum (FBS) (PAA Laboratories, A15-101). For details of
other cell lines see Materials and Methods S1. Where indicated,
medium was supplemented with 10% dextran charcoal stripped
FBS (PAA Laboratories, A15-119) to produce a steroid-deplete
medium. In experiments performed in quadruplicate, LNCaP cells
were cultured for 72 hours, following which 10 nM synthetic
androgen analogue methyltrienolone (R1881) (Perkin–Elmer,
NLP005005MG) was added (treatment; n = 4) or absent (control;
n = 4) for 24 hours. Cells were then harvested and total RNA
extracted using TRIzol (Invitrogen, 15596-026) according to
manufacturer’s instructions as previously described [9]. To ensure
array findings were not due to batch effects and to confirm the
reproducibility of validation methodologies, the above experiment
was performed independently in triplicate and all samples analysed
by qPCR and RT-PCR in an identical manner. Where indicated,
LNCaP cells were pre-treated for 1 hour with vehicle (dimethyl-
sulfoxide; DMSO) (Sigma, C1988) or 1 mg/ml cycloheximide
(Sigma, D2438) prior to addition of 10 nM R1881 for 24 hours as
previously described [39].
Figure 4. Expression of novel mRNA isoforms is both directly and indirectly regulated by androgens. (A) UCSC Genome Browser
showing chromosomal locations and annotated transcript details for each novel androgen-regulated alternative mRNA isoform. Custom tracks (black
bars below ‘‘LNCaP AR ChIP-seq peaks’’) for each gene show locations of AR binding site(s) within the LNCaP genome as determined by ChIP-Seq [4].
(B) Fluorescent quantification of capillary agarose gel electrophoretic analysis of RT-PCR products amplified from mRNA from LNCaP cells pretreated
for 1 hour with vehicle (DMSO) or 1 g/ml cycloheximide (CHX) prior to addition of 10 nM R1881 for 24 hours. The relative normalised expression ratio
is the contribution of the PCR product representing the alternative (androgen-regulated) transcript/constitutive transcript. Data from four
independent replicates were used to obtain the means 6 SE.
doi:10.1371/journal.pone.0029088.g004
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Clinical samples
For details of clinical samples see Materials and Methods S1.
RNA purification and array hybridization
Total RNA from treatment and control experiments (n = 8) was
purified using RNeasy Plus Kit (Qiagen, 74134), which includes
genomic DNA (gDNA) eliminator column to remove contaminat-
ing DNA accordingly to the manufacturer’s instructions. Ribo-
somal RNA (rRNA) reduction was performed using the RiboMi-
nus Kit (Invitrogen, K1550-02). RNA quality was verified by
analysis on the 2100 Bioanalyzer (Agilent). One microgram of total
RNA was labelled according to the GeneChip Whole Transcript
(WT) Sense Target Labelling Assay provided by the manufacturer
(Affymetrix, 900670) and hybridized to Human Exon 1.0 ST
Arrays (Affymetrix, 900649) overnight before scanning in an
Affymetrix GCS 3000 7G scanner. Raw data has been deposited
at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE 32875 and all details are
MIAME compliant.
Data analysis
Following Quality Assessment of datasets [40], gene expression
values were obtained by quantile-normalisation using Robust
Multichip Analysis (RMA) with core probesets (228,940 probesets),
and antigenomic background probes [40]. After summarization,
the Student’s T-test was used to detect differential expression
between control and treatment arrays. Only probe sets that were
detected above background (defined by detection above back-
ground; DABG p#0.01) were included in the analysis. The False
discovery rate (FDR) was calculated to make corrections of
multiple testing, using the Q-value program [41], with q,0.005
taken to indicate statistical significance. Gene Ontology (GO)
annotations for all human genes obtained from http://www.
geneontology.org, was compared with annotations for the set of
genes up-regulated following androgen treatment. We calculated
whether a term occurs proportionally more in the input set than in
the entire genome and determined if the difference was significant
using a Fisher’s Exact test which returned a P-value. FDR q= 0.05
was used to determine a cut off, and the obtained list of terms was
filtered so that terms that were significant only because one (and
only one) of their descendant terms was significant were removed.
Gene lists were uploaded to the web-based Ingenuity Pathway
Analysis (IPA; Ingenuity Systems) software programme, and the
‘‘Core Analysis’’ function was used to study direct and indirect
regulatory relationships between genes and their known biological
functions.
For detection of alternative splicing, the student’s T-test was
performed on ‘‘normalized’’ probeset intensities, which were
obtained by removal of core meta probeset intensities (gene level
estimates) from extended probeset intensities (exon level estimates).
Iter-PLIER algorithm was used for gene level estimates, and the
PLIER algorithm was used for exon level estimates [40]. To
improve the accuracy of gene expression estimation, only those
meta probesets with$11 core probes were used. Other genes were
excluded from the analysis. 16,309 of 17,881 meta probesets
passed this filtering. After the T-test for differential splicing, the
following filtering criteria were applied to identify differentially
spliced probe sets: a) The gene is expressed in both conditions and
DABG p#0.01 at least in three replicates in each condition; b) The
reliability of gene level estimates was tested by extracting the probe
intensities for each meta probeset, obtaining an average across
replicates for each condition, and ensuring good correlation
(Pearson product-moment and Spearman’s rank correlation
coefficient$0.7) between conditions; c) Gene expression between
conditions should not exceed 10 fold (3.32 in the log2 scale); d)
The T-test of normalized probe set intensities yields p#0.001 (or
p#0.0005); e) The exon must have detectable expression at least in
one condition. More specifically, the DABG P-value at the probe
set level must be #0.01 in three replicates in either condition. In
addition, in this condition, the probe set intensity must be in an
appropriate range compared with gene expression level (between
1/5 and 5, or 22.32 and 2.32 in the log2 scale).
Differentially spliced probe sets were mapped to alternative
splicing events (including cassette exons, alternative 59 and 39 splice
sites and mutually exclusive exons), as well as alternative first exons
(alternative 59 ends/promoter selection) and alternative last exons
(alternative 39 ends/polyadenylation). Alternative splicing events
were obtained from the dbCASE database (http://rulai.cshl.edu/
dbCASE) and alternative first and last exons were derived from
UCSC known genes. We limited our analysis to alternative
transcripts which had full length annotated UCSC/RefSeq
sequences with known exon structures [42]. Probe data were
visualised in their gene context using the EASANA visualisation
module (GenoSplice Technology), and candidate transcripts were
inspected using EASANA and the UCSC Genome Browser. We
focused our search on cassette exons and changes in 59-ends of
transcripts selecting candidates for RT-PCR validation. For
positively-validated targets, changes in peptide features of translated
proteins resulting from alternative mRNA isoforms were identified
using FAST-DB [27,43], identifying conserved domains using the
NCBI webpage (http://www.ncbi.nlm.nih.gov/sites/entrez) and
the UCSC Genome Browser (http://genome.ucsc.edu/) [24].
qPCR, RT-PCR and sequencing
cDNA was generated by reverse transcription of 1 mg of total
RNA using the Superscript VILO cDNA synthesis kit (Invitrogen,
11754-050) according to manufacturers instructions. Quantitative
PCR (qPCR) (Applied Biosystems 7900HT) was performed in
Figure 5. The association of AR with an alternative internal promoter region within TSC2 correlates with dynamic expression of an
alternative TSC2 mRNA. (A) Fluorescent quantification of capillary agarose gel electrophoretic analysis of RT-PCR products amplified from mRNA
from LNCaP cells pretreated for 1 hour with vehicle (DMSO) or 1 g/ml cycloheximide (CHX) prior to addition of 10 nM R1881 for 24 hours. The relative
normalised expression ratio is the contribution of the PCR product representing the 39 transcript end/59 transcript end. Data from four independent
replicates were used to obtain the means 6 SE. (B) Cartoon of intron/exon structure of TSC2 gene, showing alternative promoter upstream of exon
33. The androgen-regulated exons are shown in black, and constitutive exons are indicated in white. The position of both alternative promoters DP1
and DP2 controlling expression of the shorter TSC2 variant mRNA is asterisked. (C) LNCaP cells cultured in steroid-deplete medium for 47 hours were
treated with 10 nM R1881 for up to 120 min at 60 min intervals prior to ChIP analysis using anti-AR antisera. Input and immunoprecipitated material
were analysed by real-time PCR, using primers for the DP1 (left panel) and DP2 (right panel) regions of the downstream promoter regions upstream
of exon 33, as well as a non-AR-binding region within GREB1 (control). Data shown are means6 SE from three independent experiments. (D) Capillary
agarose gel electrophoretic analysis (upper panel) of RT-PCR products amplified from mRNA from cells grown either in steroid-deplete medium (lane
1) or following treatment with 10 nM R1881 (lanes 2–6) at timepoints upto 24 hours as shown. The predicted mRNA isoforms detected are shown to
the right of each gel exactly as summarised in Figure 2B. Fluorescent quantification (lower panel) was performed to obtain the relative normalised
expression ratio, which is the contribution of the PCR product representing the 39 transcript end/59 transcript end. The gel image (upper panel) is
representative of three independent replicates from which data were used to obtain the means 6 SE (lower panel).
doi:10.1371/journal.pone.0029088.g005
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triplicate on cDNA and gDNA templates using Platinum SYBR
Green qPCR Super Mix-UDG with ROX (Invitrogen, 11744-500)
as previously described [44]. PCR using 1 ml of 20-fold diluted
cDNA was performed for 30 cycles with Phusion High Fidelity
DNA Polymerase (Finnzymes, F-530S). All primer sequences are
listed in Table S3. RT-PCR products were initially analyzed on 2–
3% agarose gels, and subsequently using the QIAxcel capillary gel
electrophoresis system (Qiagen), which was also used for image
acquisition. Ratios between products representing transcripts of
interest multiplexed with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) controls as well as mRNA isoforms were determined
using QIAxcel software. The relative normalised gene expression
was calculated as a ratio of the fluorescent intensity of the band
representing amplification of the transcript of interest/fluorescent
intensity of band representing amplification of GAPDH). The
relative normalised expression ratio was calculated as follows:
fluorescent intensity of band representing the alternative (andro-
gen-regulated) transcript/fluorescent intensity of band or fluores-
cent intensity of band representing 39 transcript end/59 transcript
end. The independent sample T-Test was employed to identify
statistically significant differences in total transcript and alternative
mRNA isoform expression with p,0.05 taken to indicate statistical
significance. To confirm the identities of RT-PCR products
distinct gel bands were purified with the QIAquick Gel Extraction
kit (Qiagen, 28704), cloned using a CloneJET PCR Cloning Kit
(Fermentas Life Sciences, K1231) and positive transformants were
sequenced (GATC Biotech) using a T7 sequencing primer.
Chromatin Immunoprecipitation (ChIP) assays
ChIP assays were performed as previously described [44], using
2 mg anti-AR antisera and normal IgG controls. qPCR (Applied
Biosystems 7900HT) was performed on inputs and recovered
material to assess AR association to DP (downstream promoter) 1
and 2, and non-AR-binding region within GREB1 (chromosome
positions chr16:2132598–2132747, chr16:2133122–2133271, and
chr2:11597650–11597669, respectively). All experimental results
shown are the means of at least three independent experiments 6
standard error (SE).
Supporting Information
Materials and Methods S1
(DOCX)
Figure S1 Analysis of androgen-regulated gene expres-
sion. (A) Experimental validation of changes in KLK3 gene
expression. LNCaP cells were grown in steroid-deplete medium
for 72 hours followed by treatment (n = 4) or absent (n = 4) for
24 hours with 10 nM R1881. KLK3 and GAPDH transcript
expression was analysed by qPCR analysis KLK3 transcript levels
were normalised to GAPDH levels. Data from qPCR triplicates
were used to obtain the mean 6 SE for each sample. (B) Principal
Component Analysis (PCA) mapping of microarray datasets show
segregation into control (Ctr) and androgen treatment (And)
conditions. (C) Scatterplot showing gene expression in steroid-
deplete medium and following androgen treatment. Differentially-
expressed genes are shown in red ($2-fold change in gene
expression with a q-value#0.005). (D) Gene Ontology (GO)
analysis of genes up-regulated in response to androgen treatment.
(EPS)
Figure S2 Dose-independent androgen-regulation of
alternative mRNA isoforms occurs with synthetic and
natural androgens. Fluorescent quantification of capillary
agarose gel electrophoretic analysis of RT-PCR products ampli-
fied from mRNA from LNCaP cells grown in steroid-deplete
medium or after 24 hours of treatment with different concentra-
tions of synthetic (R1881) and natural (dihydrotestosterone; DHT)
androgens. The relative normalised expression ratio is the
contribution of the PCR product representing the alternative
(androgen-regulated) transcript/constitutive transcript or 39 tran-
script end/59 transcript end. Data from three independent
replicates were used to obtain the means 6 SE.
(TIF)
Figure S3 Androgen-regulated mRNAs isoforms are
expressed in benign and malignant prostate cell lines
and cases of clinical PCa. (A) Capillary agarose gel
electrophoretic analysis of RT-PCR products amplified from
mRNA from prostate epithelial cell lines. LNCaP-AI and LNCaP-
cdxR cells are able to grow in steroid-deplete medium and
medium containing anti-androgens (bicalutamide), respectively.
The predicted mRNA isoforms detected are shown to the right of
the gel exactly as summarised in Figure 2B. (B) Fluorescent
quantification of capillary agarose gel electrophoretic analysis of
RT-PCR products amplified from mRNA from PCa cell lines that
do not exhibit an androgen-dependent transcriptional response
(PC-3, PC-3M, DU145). Cells were grown either in steroid-deplete
medium or after 24 hours of treatment with 10 nM R1881. Data
from three independent replicates were used to obtain the means
6 SE. (C) Agarose gel electrophoretic analysis of RT-PCR
products amplified from mRNA from clinical prostate samples
from patients with hormone-naı¨ve (HN) (odd lanes) and following
development of castration-resistant (CR) (even lanes) disease
(n = 10). The predicted mRNA isoforms detected are shown to
the right of the gel exactly as summarised in Figure 2B. As a
control to demonstrate mRNA integrity and overall levels of gene
expression between patients, equal levels of GAPDH could be
detected in each of the patient mRNA samples. Densitometric
band quantification was performed to obtain the relative
normalised expression ratio, which is the contribution of the
PCR product representing the alternative (androgen-regulated)
transcript/constitutive transcript (data not shown). M = 1 Kb plus
DNA ladder (Invitrogen).
(TIF)
Figure S4 Expression of novel mRNA isoforms is both
directly and indirectly regulated by androgens. (A) UCSC
Genome Browser showing chromosomal locations and annotated
transcript details for each novel androgen-regulated alternative
mRNA isoform. Custom tracks (black bars below ‘‘Human_LN-
CaP_AR_R1881(16h)_Chinnaiyan’’) for each gene show locations
of AR binding site(s) within the LNCaP genome as determined by
ChIP-Seq [34].
(TIF)
Table S1 Androgen-regulated gene expression changes.
Individual gene expression changes following androgen treatment
are shown with fold change predicted based upon microarray
prediction, and the actual fold change where measured by RT-
PCR. Androgen-regulated genes identified previously published
studies are indicated. The functions and associated processes of
each gene are annotated where known.
(XLS)
Table S2 Overlap of identified androgen-regulated
genes with previously-published datasets.
(DOC)
Table S3 Genomic sequence of oligonucleotide prim-
ers. (A) qPCR for gene expression analysis (B) RT-PCR for
splicing analysis (C) RT-PCR for gene expression analysis (D)
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qPCR for ChIP analysis. Where possible, primers were designed
so that amplicons spanned exon junctions. Where shown predicted
amplicon sizes was obtained using the in silico PCR program
http://genome.ucsc.edu/index.html?org = Hu-
man&db = hg18&hgsid = 142437216.
(DOC)
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